San Diego skin cancer diagnostics startup DermTech is developing gene classifiers and expression tests to help more accurately screen for dermatologic issues.
It just raised $2.4 million to do so, according to a regulatory filing – an interesting funding notice, given its announcement last year that it was readying for – and then withdrawing – a $25 million IPO. Poor market conditions, it said. Renaissance Capital writes:
The La Jolla, CA-based company was founded in 1995 and booked $0 million in sales for the 12 months ended June 30, 2014. DMTK. DermTech initially filed confidentially on 4/4/2014.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company’s lead assay is tests pigmented lesions for gene expression that matches melanoma. It’s a noninvasive test that could, ostensibly, cut down on unnecessarily surgical biopsies. Actually, the company just gave notice that it received a patent for this test.
The tests work by extracting RNA from skin tissue samples that are collected by stripping a negligible amount of skin off with an adhesive patch. Using this RNA, it then analyzes the expression of melanoma-associated genes.
[Image from flickr user Christiana Care]
